Harmony Biosciences Holdings, Inc.

HRMY Nasdaq SEC CIK 1802665
Follow Harmony Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $268.9M +12.3% vs same quarter last year
Net income $48.2M −5.2% vs same quarter last year
EPS, diluted $0.81 −6.9% vs same quarter last year
Operating cash flow $76.7M −29.5% vs same quarter last year
Revenue by quarter
$201.3M
$184.7M
$200.5M
$239.5M
$243.8M
$215.4M
$261.3M
$268.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$868.5M$158.7M
FY24$714.7M$145.5M
FY23$582M$128.9M
FY22$437.9M$181.5M
FY21$305.4M$34.6M
FY20$159.7M−$36.9M
FY19$6M−$152M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%1000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2577.2%24%18.3%
FY2478.1%26.7%20.4%
FY2379.2%33%22.1%
FY2280.9%27.4%41.4%
FY2181.8%28.7%11.3%
FY2082.6%10.6%−23.1%
FY1973.7%−2433.8%−2535.1%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$200M$0$200M$400MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$347.9M
FY24$218.7M
FY23$219.1M
FY22$144.3M
FY21$98.3M
FY20−$3M
FY19−$75.6M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Harmony Biosciences
  • Healthcare median
−3000%−2000%−1000%0%1000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearHarmony BiosciencesHealthcare median
FY2518.3%−30.6%
FY2420.4%−47%
FY2322.1%−58%
FY2241.4%−80.4%
FY2111.3%−71.8%
FY20−23.1%−62.2%
FY19−2535.1%−46.2%
FY18-−49.6%